Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A multi-institutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial

Journal of Clinical Oncology

Volumn 15, Issue 5, 1997, Pages 1844-1852

  Horwich, A ^a   Sleijfer, D T ^a   Fossa S D ^a   Kaye, S B ^a   Oliver, R T D ^a   Cullen, M H ^a   Mead, G M ^a   de Wit, R ^a   de Mulder, P H M ^a   Dearnaley, D P ^a   Cook, P A ^a   Sylvester, R J ^a   Stenning, S P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; NON SEMINOMATOUS GERMINOMA; OTOTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030939778     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.5.1844     Document Type: Article

References (20)

1. Medical Research Council, Working Party on Testicular Tumours: Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: Results of a multicentre study. Lancet 1:8-12, 1985
2. Mead GM, Stenning SP, Parkinson MC, et al: The second Medical Research Council Study of prognostic factors in nonseminomatous germ cell tumors. J Clin Oncol 10:85-94, 1992
3. Bosl GJ, Geller N, Bajorin D, et al: A randomized trial of etoposide + cisplatin versus VAB-6 (vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin) in patients with good prognosis germ cell tumor. J Clin Oncol 6:1231-1238, 1988
4. Einhorn LH, Williams SD, Loehrer PJ, et al: Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol. J Clin Oncol 7:387-391, 1989
5. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors: With cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
6. Horwich A: Germ cell tumour chemotherapy. Br J Cancer 59:156-159, 1989
7. Horwich A: Management of metastatic non-seminoma: Toxicity reduction by replacement of cisplatin by carboplatin, in Horwich A (ed): Testicular Cancer - Clinical Investigation and Management. London, United Kingdom, Chapman & Hall Medical, 1991, pp 213-220
8. Motzer R, Cooper K, Geller NL: Carboplatin, etoposide, and bleomycin for patients with poor risk germ cell tumors. Cancer 65:2465-2470, 1990
9. Childs WJ, Nicholls EJ, Horwich A: The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis. Ann Oncol 3:291-296, 1992
10. Levi J, Raghavan D, Harvey V, et al: Deletion of bleomycin from therapy for good prognosis advanced testicular cancer: A prospective randomized study. Proc Am Soc Clin Oncol 5:97, 1986 (abstr)
11. Stoter G: Preliminary results of BEP (bleomycin, etoposide, cisplatin) versus EP in low volume metastatic (LVM) testicular non-seminomas. An EORTC study. Proc Am Soc Clin Oncol 6:110, 1987 (abstr)
12. Bajorin DF, Sarosdy MF, Pfister DG, et al: Randomised trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multi-institutional study. J Clin Oncol 11:598-606, 1993
13. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
14. Horwich A: Testicular germ cell tumours: An introductory overview, in Horwich A (ed): Testicular Cancer - Investigation and Management (ed 2). London, United Kingdom, Chapman & Hall, 1996, pp 1-17
15. Harding MJ, Paul J, Gillis CR, et al: Management of malignant teratoma: Does referral to a specialist unit matter? Lancet 314:999-1002, 1993
16. Stoter G, Sleijfer DT, Schornagel JH, et al: BEP versus VIP in intermediate risk patients with disseminated non-seminomatous testicular cancer (NSTC). Proc Am Soc Clin Oncol 12:232, 1993 (abstr)
17. Levi J, Raghaven D, Harvey V, et al: The importance of bleomycin in combination chemotherapy for good prognosis germ cell carcinoma. J Clin Oncol 11:1300-1305, 1993
18. Loehrer PJ, Johnson D, Elson P, et al: Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial. J Clin Oncol 13:470-476, 1995
19. Stoter G, Bosl GJ, Droz JP, et al: Prognostic factors in metastatic germ cell tumors, in Newling DWW, Jones WG (eds): EORTC Genitouinary Group Monograph 7. New York, NY, Wiley-Liss, 1990, pp 313-319
20. Birch R, Williams S, Cone A, et al: Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4:400-407, 1986